SKF83959 is a potent allosteric modulator of sigma-1 receptor

Molecular Pharmacology

Volumn 83, Issue 3, 2013, Pages 577-586

  Guo, Lin ^a   Zhao, Jianghao ^a   Jin, Guozhang ^c   Zhao, Bin ^d   Wang, Guanghui ^b   Zhang, Ao ^a   Zhen, Xuechu ^a,b  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b SOOCHOW UNIVERSITY   (China)

^c GUANGDONG MEDICAL UNIVERSITY   (China)

^d SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; PHENYTOIN; SIGMA 1 OPIATE RECEPTOR;

ALLOSTERISM; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN TISSUE; CELL STRAIN HEK293; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; LIVER; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ALLOSTERIC REGULATION; ANIMALS; BRAIN; CELL LINE; DRUG SYNERGISM; HEK293 CELLS; HUMANS; LIVER; MALE; PENTAZOCINE; PROGESTERONE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, SIGMA;

EID: 84874304655     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.083840     Document Type: Article

References (46)

1. Andringa G, Drukarch B, Leysen JE, Cools AR, and Stoof JC (1999a) The alleged dopamine D1 receptor agonist SKF 83959 is a dopamine D1 receptor antagonist in primate cells and interacts with other receptors. Eur J Pharmacol 364:33-41. (Pubitemid 29015784)
2. Andringa G, Stoof JC, and Cools AR (1999b) Sub-chronic administration of the dopamine D(1) antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: Stable therapeutic effects and wearing-off dyskinesia. Psychopharmacology (Berl) 146:328-334. (Pubitemid 29480245)
3. Aydar E, Palmer CP, Klyachko VA, and Jackson MB (2002) The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 34:399-410. (Pubitemid 34465498)
4. Bruns RF and Fergus JH (1990) Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol 38:939-949.
5. Cagnotto A, Bastone A, and Mennini T (1994) [3H](1)-pentazocine binding to rat brain sigma 1 receptors. Eur J Pharmacol 266:131-138.
6. Chen XQ, Zhang J, Neumeyer JL, Jin GZ, Hu GY, Zhang A, and Zhen X (2009) Arylbenzazepines are potent modulators for the delayed rectifier K1 channel: A potential mechanism for their neuroprotective effects. PLoS ONE 4:e5811.
7. Cheng ZX, Lan DM, Wu PY, Zhu YH, Dong Y, Ma L, and Zheng P (2008) Neurosteroid dehydroepiandrosterone sulphate inhibits persistent sodium currents in rat medial prefrontal cortex via activation of sigma-1 receptors. Exp Neurol 210:128-136. (Pubitemid 351258075)
8. Christopoulos A(2000) Quantification of allosteric interactions at G proetin-coupled receptors using radioligand binding assays, in Current Protocols in Pharmacology (Enna S ed) pp 1.22.21-21.22.40, Willy and Sons, New York.
9. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374. (Pubitemid 34575719)
10. Chu HY, Wu Q, Zhou S, Cao X, Zhang A, Jin GZ, Hu GY, and Zhen X (2011) SKF83959 suppresses excitatory synaptic transmission in rat hippocampus via a dopamine receptor-independent mechanism. J Neurosci Res 89:1259-1266.
11. Chu HY, Yang Z, Zhao B, Jin GZ, Hu GY, and Zhen X (2010) Activation of phosphatidylinositol-linked D1-like receptors increases spontaneous glutamate release in rat somatosensory cortical neurons in vitro. Brain Res 1343:20-27.
12. Cobos EJ, Baeyens JM, and Del Pozo E (2005) Phenytoin differentially modulates the affinity of agonist and antagonist ligands for sigma 1 receptors of guinea pig brain. Synapse 55:192-195. (Pubitemid 40194721)
13. Cobos EJ, Entrena JM, Nieto FR, Cendán CM, and Del Pozo E (2008) Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol 6: 344-366.
14. Cobos EJ, Lucena G, Baeyens JM, and Del Pozo E (2006) Differences in the allosteric modulation by phenytoin of the binding properties of the sigma1 ligands [3H](1)-pentazocine and [3H]NE-100. Synapse 59:152-161. (Pubitemid 43121919)
15. Cools AR, Lubbers L, van Oosten RV, and Andringa G (2002) SKF 83959 is an antagonist of dopamine D1-like receptors in the prefrontal cortex and nucleus accumbens: A key to its antiparkinsonian effect in animals? Neuropharmacology 42:237-245. (Pubitemid 34137027)
16. DeHaven-Hudkins DL, Ford-Rice FY, Allen JT, and Hudkins RL (1993) Allosteric modulation of ligand binding to [3H](1)pentazocine-defined sigma recognition sites by phenytoin. Life Sci 53:41-48.
17. Dong LY, Cheng ZX, Fu YM, Wang ZM, Zhu YH, Sun JL, Dong Y, and Zheng P (2007) Neurosteroid dehydroepiandrosterone sulfate enhances spontaneous glutamate release in rat prelimbic cortex through activation of dopamine D1 and sigma-1 receptor. Neuropharmacology 52:966-974. (Pubitemid 46227485)
18. Fujita S, Kiguchi M, Kobayashi M, Kinsella A, Koshikawa N, and Waddington JL (2010) Assessment of jaw movements by magnetic sensor in relation to topographies of orofacial behaviour in freely moving rats: Studies with the dopamine D(1)-like receptor agonists SKF 83822 vs SKF 83959. Eur J Pharmacol 632:39-44.
19. Gnanalingham KK, Hunter AJ, Jenner P, and Marsden CD (1995) Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease-the differential effects of D1 dopamine antagonists in the primate. Psychopharmacology (Berl) 117:403-412.
20. González LG, Portillo E, Del Pozo E, and Baeyens JM (2001) Changes in [(3)H]glibenclamide binding to mouse forebrain membranes during morphine tolerance. Eur J Pharmacol 418:29-37. (Pubitemid 32378807)
21. Hall DA (2000) Modeling the functional effects of allosteric modulators at pharmacological receptors: An extension of the two-state model of receptor activation. Mol Pharmacol 58:1412-1423.
22. Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, and Glossmann H (1996) Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA 93:8072-8077. (Pubitemid 26277167)
23. Hayashi T and Su T (2005) The sigma receptor: Evolution of the concept in neuropsychopharmacology. Curr Neuropharmacol 3:267-280. (Pubitemid 41461244)
24. Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, and Bowen WD (1994) Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: Characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol 268:9-18.
25. Jin LQ, Goswami S, Cai G, Zhen X, and Friedman E (2003) SKF83959 selectively regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain. J Neurochem 85:378-386. (Pubitemid 36438333)
26. Kekuda R, Prasad PD, Fei YJ, Leibach FH, and Ganapathy V (1996) Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem Biophys Res Commun 229:553-558. (Pubitemid 27029069)
27. Makihara Y, Okuda Y, Kawada C, Matsumoto M, Waddington JL, Koshikawa N, and Tomiyama K (2007) Differential involvement of cyclase-versus non-cyclasecoupled D1-like dopamine receptors in orofacial movement topography in mice: Studies with SKF 83822. Neurosci Lett 415:6-10. (Pubitemid 46356711)
28. Mei J and Pasternak GW (2001) Molecular cloning and pharmacological characterization of the rat sigma1 receptor. Biochem Pharmacol 62:349-355. (Pubitemid 32575336)
29. Meyer DA, Carta M, Partridge LD, Covey DF, and Valenzuela CF (2002) Neurosteroids enhance spontaneous glutamate release in hippocampal neurons. Possible role of metabotropic sigma1-like receptors. J Biol Chem 277:28725-28732.
30. Ming Y, Zhang H, Long L, Wang F, Chen J, and Zhen X (2006) Modulation of Ca21 signals by phosphatidylinositol-linked novel D1 dopamine receptor in hippocampal neurons. J Neurochem 98:1316-1323. (Pubitemid 44127804)
31. Noriyama Y, Ogawa Y, Yoshino H, Yamashita M, and Kishimoto T (2006) Dopamine profoundly suppresses excitatory transmission in neonatal rat hippocampus via phosphatidylinositol-linked D1-like receptor. Neuroscience 138:475-485. (Pubitemid 43255558)
32. O'Sullivan GJ, Clifford JJ, Tomiyama K, Koshikawa N, Drago J, Sibley DR, Croke DT, and Waddington JL (2004) D1-like dopamine receptor-mediated function in congenic mutants with D1 vs. D5 receptor "knockout". J Recept Signal Transduct Res 24:107-116. (Pubitemid 39332212)
33. Pal A, Hajipour AR, Fontanilla D, Ramachandran S, Chu UB, Mavlyutov T, and Ruoho AE (2007) Identification of regions of the sigma-1 receptor ligand binding site using a novel photoprobe. Mol Pharmacol 72:921-933. (Pubitemid 47481415)
34. Palmer CP, Mahen R, Schnell E, Djamgoz MB, and Aydar E (2007) Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines. Cancer Res 67: 11166-11175. (Pubitemid 350248541)
35. Panchalingam S and Undie AS (2001) SKF83959 exhibits biochemical agonism by stimulating [(35)S]GTP gamma S binding and phosphoinositide hydrolysis in rat and monkey brain. Neuropharmacology 40:826-837. (Pubitemid 32436459)
36. Prezzavento O, Campisi A, Ronsisvalle S, Li Volti G, Marrazzo A, Bramanti V, Cannavò G, Vanella L, Cagnotto A, and Mennini T et al. (2007) Novel sigma receptor ligands: Synthesis and biological profile. J Med Chem 50:951-961. (Pubitemid 46393998)
37. Rashid AJ, O'Dowd BF, Verma V, and George SR (2007) Neuronal Gq/11-coupled dopamine receptors: An uncharted role for dopamine. Trends Pharmacol Sci 28:551-555. (Pubitemid 350026611)
38. Sahu A, Tyeryar KR, Vongtau HO, Sibley DR, and Undieh AS (2009) D5 dopamine receptors are required for dopaminergic activation of phospholipase C. Mol Pharmacol 75:447-453.
39. Seth P, Fei YJ, Li HW, Huang W, Leibach FH, and Ganapathy V (1998) Cloning and functional characterization of a sigma receptor from rat brain. J Neurochem 70: 922-931. (Pubitemid 28113624)
40. Sun P, Wang J, Gu W, Cheng W, Jin GZ, Friedman E, Zheng J, and Zhen X (2009) PSD-95 regulates D1 dopamine receptor resensitization, but not receptor-mediated Gs-protein activation. Cell Res 19:612-624.
41. Undieh AS (2010) Pharmacology of signaling induced by dopamine D(1)-like receptor activation. Pharmacol Ther 128:37-60.
42. Yu Y, Wang JR, Sun PH, Guo Y, Zhang ZJ, Jin GZ, and Zhen X (2008) Neuroprotective effects of atypical D1 receptor agonist SKF83959 are mediated via D1 receptor-dependent inhibition of glycogen synthase kinase-3 beta and a receptorindependent anti-oxidative action. J Neurochem 104:946-956. (Pubitemid 351146579)
43. Zhang H and Cuevas J (2002) Sigma receptors inhibit high-voltage- activated calcium channels in rat sympathetic and parasympathetic neurons.JNeurophysiol 87:2867-2879. (Pubitemid 34670667)
44. Zhang H, Ma L, Wang F, Chen J, and Zhen X (2007) Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDAlesioned rat model of Parkinson's disease. Neuropharmacology 53:125-133. (Pubitemid 47125943)
45. Zhang L, Peng X, Zhang Z, Feng Y, Jia X, Shi Y, Yang H, Zhang Z, Zhang X, and Liu L et al. (2010) Subcellular proteome analysis unraveled annexin A2 related to immune liver fibrosis. J Cell Biochem 110:219-228.
46. Zhen X, Goswami S, and Friedman E (2005) The role of the phosphatidyinositollinked D1 dopamine receptor in the pharmacology of SKF83959. Pharmacol Biochem Behav 80:597-601. (Pubitemid 41583208)